Drug Trial Radar · NCT05704725
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
Last checked: Nov 19, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jan 23, 2023
Primary completion
Feb 17, 2023
Study completion Mar 24, 2023
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jan 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
Conditions
- Chorioretinal Vascular Disease
Interventions
ABP 938Drug
IVT injection
AfliberceptDrug
IVT injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of IVT Injections Successfully AdministeredTime frame: Day of IVT injection (study day 1)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Retina Consultants of Texas - Austin Retina
Austin, Texas
Retina Consultants of Texas - Bellaire Retina Center
Bellaire, Texas
Retinal Consultants of Texas - San Antonio Retina Center
San Antonio, Texas
Retina Consultants of Texas - The Woodlands Retina Center
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.